进展期胃肠癌术后腹腔淋巴化疗联合静脉化疗的临床观察

Clinical Observation of Chemical Therapies Via Abdominal Cavity and Vein after Resection of Advanced Gastric Cancer and Large Intestine Cancer

目的:研究进展期胃肠道癌根治性术后腹腔淋巴化疗联合静脉化疗的临床疗效。方法:对1996年1月至2001年12月经术前病理学确诊的480例胃肠道癌病人行根治性手术后,分阶段行腹腔化疗(A组)160例(1996年1月至1997年12月),腹腔免疫化疗(B组)160例(1998年1月至1999年12月),腹腔淋巴化疗联合静脉化疗(C组)160例(2000年1月至2001年12月),化疗方案分别为腹腔注入FDM、腹腔注入FDM+干扰素α2b、腹腔注入FDM+静脉注入垂体后叶素+静脉注入5Fu,并将3组病人在术后化疗毒副作用、局部复发、腹腔内局部复发、肝转移、腹腔内淋巴结和腹膜后淋巴结转移及术后3年生存期进行分析研究。结果:480例病人术后均完成了6个疗程的化疗,术后3组病人化疗毒副作用、腹腔内局部复发、肝转移无显著性差异,术后腹膜后淋巴结转移C组明显低于A、B两组,术后3年生存期C组明显高于A、B两组,有显著性差异。结论:腹腔淋巴化疗联合静脉化疗是进展期胃肠道癌术后良好的化疗方法。

Objective:To explore treatment effect of lymphatic chemical thrapies abdominal cavity and vein chemical after resection of advanced gastric cancer and large intestine cancer. Methods:Four hundred and eighty cases of advanced gastric cancer and large intestine cancer(1996.01~2001.12)were divided into chemical therapies abdominal cavity group(160 cases 1996.01~1997.12)、 chemo-immunotherapy group(160 cases 1998.01~1999.12)and lymphatic chemical thrapies abdominal cavity and vein chemical group(160 cases 2000.01~2001.12). The chemical therapies programe were treated with FDM programe, FDM+α-2b, FDM+vein used Vasopressin and 5-Fu. Three group were compared and studyed for chemical thrapy side effect, area recurrence, abdominal cavity area recurrence, hepatic metastasis, lymph note of abdominal cavity and behind abdominal metastasis and 3-year survival rate. Results:All cases finised the 6 phases of chemotherapy. 3 groups were compared in multiply factory. Lymph note of abdominal cavity and behind abdominal metastasis rate were much less. The 3 year survival rates were much higher in group C than those of group A and B. Conclusion:Lymphatic chemical thrapies abdominal cavity and vein chemical is much better chemical thrapy after resection of advanced gastric cancer and large intestine cancer .